Cargando…
Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?
Digitalization of any manufacture industry is a key step in any progress of the production process. The process of digitalization includes both increased use of robotics, automatization solutions and computerization, thereby allowing to reduce costs, to improve efficiency and productivity, and to be...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528719/ https://www.ncbi.nlm.nih.gov/pubmed/34712948 http://dx.doi.org/10.1016/j.ijpx.2021.100095 |
_version_ | 1784586308207771648 |
---|---|
author | Hole, Glenn Hole, Anastasia S. McFalone-Shaw, Ian |
author_facet | Hole, Glenn Hole, Anastasia S. McFalone-Shaw, Ian |
author_sort | Hole, Glenn |
collection | PubMed |
description | Digitalization of any manufacture industry is a key step in any progress of the production process. The process of digitalization includes both increased use of robotics, automatization solutions and computerization, thereby allowing to reduce costs, to improve efficiency and productivity, and to be flexible to changes. Pharmaceutical Industry (PI) has however been resistant to digitalization, mainly due to fair experience and complexity of the entailed development and manufacture processes. Nevertheless, there is a clear need to digitalize PI as the demand in both traditional and new drugs is constantly growing. Contract Development Manufacture Organizations (CDMOs) have a special digitalizing challenge. Digitalization of PI, and CDMO precisely, should be tightly related to the main aspects of Good Manufacture Practice (GMP), and, to succeed in PI digitalizing requires constant focus on GMP. Close collaboration with constantly changing stakeholders is another important factor which should be in focus during digitalization of CDMO. This paper represents an overview over the main aspects of CDMO digitalization and discusses both the opportunities and challenges of the process, focusing on the practical solutions for successive digital implementation. |
format | Online Article Text |
id | pubmed-8528719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-85287192021-10-27 Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? Hole, Glenn Hole, Anastasia S. McFalone-Shaw, Ian Int J Pharm X Mini Review Digitalization of any manufacture industry is a key step in any progress of the production process. The process of digitalization includes both increased use of robotics, automatization solutions and computerization, thereby allowing to reduce costs, to improve efficiency and productivity, and to be flexible to changes. Pharmaceutical Industry (PI) has however been resistant to digitalization, mainly due to fair experience and complexity of the entailed development and manufacture processes. Nevertheless, there is a clear need to digitalize PI as the demand in both traditional and new drugs is constantly growing. Contract Development Manufacture Organizations (CDMOs) have a special digitalizing challenge. Digitalization of PI, and CDMO precisely, should be tightly related to the main aspects of Good Manufacture Practice (GMP), and, to succeed in PI digitalizing requires constant focus on GMP. Close collaboration with constantly changing stakeholders is another important factor which should be in focus during digitalization of CDMO. This paper represents an overview over the main aspects of CDMO digitalization and discusses both the opportunities and challenges of the process, focusing on the practical solutions for successive digital implementation. Elsevier 2021-10-06 /pmc/articles/PMC8528719/ /pubmed/34712948 http://dx.doi.org/10.1016/j.ijpx.2021.100095 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Mini Review Hole, Glenn Hole, Anastasia S. McFalone-Shaw, Ian Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? |
title | Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? |
title_full | Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? |
title_fullStr | Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? |
title_full_unstemmed | Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? |
title_short | Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? |
title_sort | digitalization in pharmaceutical industry: what to focus on under the digital implementation process? |
topic | Mini Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528719/ https://www.ncbi.nlm.nih.gov/pubmed/34712948 http://dx.doi.org/10.1016/j.ijpx.2021.100095 |
work_keys_str_mv | AT holeglenn digitalizationinpharmaceuticalindustrywhattofocusonunderthedigitalimplementationprocess AT holeanastasias digitalizationinpharmaceuticalindustrywhattofocusonunderthedigitalimplementationprocess AT mcfaloneshawian digitalizationinpharmaceuticalindustrywhattofocusonunderthedigitalimplementationprocess |